Robert J Amato

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. doi Lenalidomide therapy for metastatic renal cell carcinoma
    Robert J Amato
    Genitourinary Oncology Program, Methodist Hospital Research Institute, Houston, TX 77030, USA
    Am J Clin Oncol 31:244-9. 2008
  2. doi Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results
    Robert J Amato
    Department of Internal Medicine, Division of Oncology, The University of Texas Health Science Center, Memorial Hermann Hospital, Houston, TX 77030, USA
    Clin Genitourin Cancer 6:73-8. 2008
  3. doi Pilot study of rapamycin in patients with hormone-refractory prostate cancer
    Robert J Amato
    University of Texas Health Science Center, Memorial Hermann Hospital, Houston, TX 77030, USA
    Clin Genitourin Cancer 6:97-102. 2008
  4. doi Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial
    Robert J Amato
    The Methodist Hospital Research Institute, Houston, Texas 77030, USA
    Clin Cancer Res 14:7504-10. 2008
  5. ncbi Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial
    Robert J Amato
    Memorial Hermann Cancer Center, The University of Texas Health Science Center, Houston, TX 77030, USA
    J Immunother 32:765-72. 2009
  6. ncbi Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer
    Robert J Amato
    The Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin Street, Suite 2050 Houston, TX 77030, USA
    J Exp Ther Oncol 7:41-7. 2008
  7. doi Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma
    Robert J Amato
    Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin Street, Suite 2050, Houston, TX 77030, USA
    Am J Clin Oncol 31:237-43. 2008
  8. ncbi Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer
    Robert J Amato
    The Methodist Hospital, The Methodist Hospital Research Institute, Genitourinary Oncology Program, Houston, TX 77030, USA
    Am J Clin Oncol 31:532-8. 2008
  9. doi Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer
    Robert J Amato
    The University of Texas Health Science Center at Houston, 6410 Fannin St Suite 830, Houston, TX 77030, USA
    Future Oncol 8:231-7. 2012
  10. ncbi Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer
    Michael T Tetzlaff
    Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, ST 2100, Houston, Texas 77030, USA
    Technol Cancer Res Treat 5:23-36. 2006

Detail Information

Publications48

  1. doi Lenalidomide therapy for metastatic renal cell carcinoma
    Robert J Amato
    Genitourinary Oncology Program, Methodist Hospital Research Institute, Houston, TX 77030, USA
    Am J Clin Oncol 31:244-9. 2008
    ..Oral lenalidomide, a thalidomide-based drug having enhanced immunomodulatory and antiangiogenic properties and reduced toxicity, was evaluated for safety and efficacy in this setting...
  2. doi Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results
    Robert J Amato
    Department of Internal Medicine, Division of Oncology, The University of Texas Health Science Center, Memorial Hermann Hospital, Houston, TX 77030, USA
    Clin Genitourin Cancer 6:73-8. 2008
    ..We evaluated the safety and efficacy of motexafin gadolinium (MGd), a Trx inhibitor, as a single-agent therapy for metastatic RCC...
  3. doi Pilot study of rapamycin in patients with hormone-refractory prostate cancer
    Robert J Amato
    University of Texas Health Science Center, Memorial Hermann Hospital, Houston, TX 77030, USA
    Clin Genitourin Cancer 6:97-102. 2008
    ..Rapamycin, an immunosuppressive macrolide, inhibits metastatic prostate tumor growth and angiogenesis in in vivo mouse models. This pilot study assessed the antitumor activity, safety, and toxicity of rapamycin in patients with HRPC...
  4. doi Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial
    Robert J Amato
    The Methodist Hospital Research Institute, Houston, Texas 77030, USA
    Clin Cancer Res 14:7504-10. 2008
    ..The safety, immunologic, and clinical efficacy of TroVax in combination with IL-2 was determined...
  5. ncbi Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial
    Robert J Amato
    Memorial Hermann Cancer Center, The University of Texas Health Science Center, Houston, TX 77030, USA
    J Immunother 32:765-72. 2009
    ..Despite the high frequency of 5T4-specific immune responses, it is not possible to conclude that patients are receiving clinical benefit. The results are encouraging and warrant further investigation...
  6. ncbi Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer
    Robert J Amato
    The Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin Street, Suite 2050 Houston, TX 77030, USA
    J Exp Ther Oncol 7:41-7. 2008
    ..A prospective investigation of this combination warranted...
  7. doi Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma
    Robert J Amato
    Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin Street, Suite 2050, Houston, TX 77030, USA
    Am J Clin Oncol 31:237-43. 2008
    ..This study assessed whether GM-CSF would improve the response rate of MRCC patients to the thalidomide plus IL-2 regimen...
  8. ncbi Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer
    Robert J Amato
    The Methodist Hospital, The Methodist Hospital Research Institute, Genitourinary Oncology Program, Houston, TX 77030, USA
    Am J Clin Oncol 31:532-8. 2008
    ..This phase II study investigated the addition of Sr-89 to an alternating weekly regimen of doxorubicin and ketoconazole with paclitaxel and estramustine in patients with progressive prostate cancer and bone involvement...
  9. doi Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer
    Robert J Amato
    The University of Texas Health Science Center at Houston, 6410 Fannin St Suite 830, Houston, TX 77030, USA
    Future Oncol 8:231-7. 2012
    ..With minimal side effects and the ability to produce a strong immunogenic response, MVA-5T4 is a viable addition to the cancer therapy arsenal...
  10. ncbi Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer
    Michael T Tetzlaff
    Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, ST 2100, Houston, Texas 77030, USA
    Technol Cancer Res Treat 5:23-36. 2006
    ..The combined approach maximizes tumor control, both local-regional and systemic through radio-genetherapy induced cytotoxicity and anti-tumor immunity...
  11. doi Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial
    Robert J Amato
    The Methodist Hospital Research Institute, Houston, Texas 77030, USA
    Anticancer Drugs 19:527-33. 2008
    ..27 (1.13-15.97) months and median overall survival (range) was 11.42+ (1.13-29.07+) months. Combination of gefitinib with interferon safely delays progression of refractory MRCC. Further studies in this setting are warranted...
  12. doi Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate
    Robert J Amato
    Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Urol Oncol 27:8-13. 2009
    ....
  13. doi A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate
    Robert J Amato
    Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Urol Oncol 27:165-9. 2009
    ..A retrospective review was conducted to evaluate results...
  14. ncbi A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma
    Robert J Amato
    The Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin Street, Suite 2050, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 61:1069-73. 2008
    ..We have conducted a phase I trial to determine the maximum tolerated dose of gemcitabine in combination with interferon, thalidomide and capecitabine...
  15. doi A phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma
    Robert J Amato
    Department of Internal Medicine, Memorial Hermann Cancer Center, Division of Oncology, University of Texas Health Science Center at Houston, Medical School, Houston, TX 77030, USA
    J Immunother 36:268-75. 2013
    ..EC90 vaccine with GPI-0100 adjuvant followed by EC17 is safe and well tolerated. The recommended regimen for further studies is 4 weekly vaccinations with 0.2 mg of EC90 plus 3.0 mg GPI-0100 followed by treatment with 0.3 mg of EC17...
  16. doi Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments
    Robert J Amato
    The University of Texas Health Science Center at Houston, Department of Internal Medicine, Division of Oncology, Houston, Texas 77030, USA
    Cancer Invest 31:177-82. 2013
    ....
  17. doi A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases
    Pavan M Jhaveri
    Department of Radiology, Section of Radiation Oncology, Baylor College of Medicine, 6565 Fannin, Houston, TX 77030, USA
    Acta Oncol 51:584-8. 2012
    ..To investigate the utility of stereotactic body radiotherapy (SBRT) in the treatment of painful renal cell carcinoma (RCC) bone metastases, and for a possible dose effect on time to symptom relief...
  18. ncbi Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study
    Robert J Amato
    Genitourinary Oncology Program, The Methodist Hospital, Research Institute, Houston, TX 77030, USA
    Invest New Drugs 24:171-5. 2006
    ..To assess the activity and toxicity of interferon-alpha (IFN-alpha), capecitabine, and thalidomide in patients with metastatic renal cell carcinoma (MRCC)...
  19. ncbi Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma
    Robert J Amato
    Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Cancer 106:1498-506. 2006
    ..The purpose of the study was to determine, in a Phase I/II study, the efficacy and safety profile of thalidomide with interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC)...
  20. ncbi Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial
    Robert J Amato
    Department of Genitourinary Oncology Program, The Methodist Hospital Research Institute, 6560 Fannin, Houston, TX 77047, USA
    J Immunother 31:577-85. 2008
    ..The high frequency of 5T4-specific immune responses and relationship with enhanced time to progression is encouraging and warrants further investigation...
  21. ncbi Therapeutic targets for metastatic prostate cancer
    Terry L Timme
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Curr Drug Targets 4:251-61. 2003
    ....
  22. pmc Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer
    Robert J Amato
    The University of Texas Health Medical School, Memorial Hermann Cancer Center, Houston, USA
    Clin Genitourin Cancer 10:232-8. 2012
    ..Genetic alterations involving the mTOR pathway have been associated with CRPC development, raising the hypothesis that blocking mTOR signaling may be an effective targeted approach to treatment...
  23. doi A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
    Robert J Amato
    Department of Internal Medicine, Division of Oncology, The University of Texas Health Medical School, Memorial Hermann Cancer Center, Houston, Texas 77030, USA
    Cancer 115:2438-46. 2009
    ..mTOR inhibitors and agents with primarily antiangiogenic activity have been shown to have efficacy in renal cell cancer (RCC). This phase 2 study assessed the efficacy of daily oral dosing with everolimus in patients with RCC...
  24. ncbi Current immunotherapeutic strategies in renal cell carcinoma
    Robert J Amato
    Genitourinary Oncology Program, The Methodist Hospital Research Institute, 6560 Fannin, Houston, TX 77030, USA
    Surg Oncol Clin N Am 16:975-86, xi-xii. 2007
    ..An additional approved tyrosine kinase inhibitor, sorafenib, is recommended as second-line therapy. More clinical research on these agents and their use in combination, especially sequentially, is warranted...
  25. doi Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study
    Robert J Amato
    The University of Texas Memorial Hermann Hospital, Houston, TX, USA
    Clin Cancer Res 16:5539-47. 2010
    ....
  26. ncbi A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer
    Robert J Amato
    The Methodist Hospital, The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Clin Genitourin Cancer 4:281-6. 2006
    ..A phase I dose-escalation study was conducted to evaluate the use of these agents in combination to enhance the chemotherapeutic effects of treatment for refractory cancer...
  27. ncbi Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis
    Robert J Amato
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    Urology 63:144-8; discussion 148-9. 2004
    ..To evaluate whether two courses of chemotherapy after orchiectomy in patients with clinical Stage I nonseminomatous germ cell testicular tumor at high risk of relapse will spare patients additional chemotherapy or surgery...
  28. ncbi Radiation therapy in the management of brain metastases from renal cell carcinoma
    Lucius S Doh
    Department of Radiology, Section of Radiation Oncology, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
    Oncology (Williston Park) 20:603-13; discussion 613, 616, 619-20 passsim. 2006
    ..Newer radiosensitizers (eg, motexafin gadolinium [Xcytrin]) and chemotherapeutic agents (eg, temozolomide [Temodar]) used in combination with radiotherapy will also be discussed...
  29. doi Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer
    Robert J Amato
    Division of Oncology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA
    Urology 81:1303-7. 2013
    ....
  30. doi Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis
    Federico A Monzon
    Department of Pathology, The Methodist Hospital Research Institute, Houston, TX, USA
    Mod Pathol 24:1470-9. 2011
    ..Further exploration of 8q gain, 14q loss, MYC, HIF1A and EPAS1 (HIF2α) as molecular markers of tumor behavior and prognosis could aid in personalizing medicine for patients with clear-cell renal cell carcinoma...
  31. ncbi Targeted anti-cancer therapies for renal cancer
    Robert J Amato
    Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, Texas 77030, USA
    Drugs 66:2161-71. 2006
    ..On the basis of the limited studies to date, targeted therapies offer the greatest clinical benefit in the management of this malignancy, although additional basic research is still warranted to further improve clinical outcome...
  32. ncbi A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma
    Robert J Amato
    Department of Internal Medicine, Division of Oncology, University of Texas Health Science Center at Houston Medical School Memorial Hermann Cancer Center Medical School, University of Texas Health Science Center at Houston, Houston, TX Endocyte Inc Department of Chemistry, Purdue University, West Lafayette, IN
    J Immunother 37:237-44. 2014
    ..Overall, folate immune plus low-dose IFN-α and IL-2 was safe and well tolerated with some observed clinical activity. ..
  33. doi Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States
    Putao Cen
    Division of Oncology, Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, TX, USA
    Ann Surg Oncol 19:1685-91. 2012
    ..Our aim was to evaluate the changes in age, stage distribution, and overall survival (OS) of patients with esophageal adenocarcinoma (EAC) over time...
  34. doi MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma
    Robert J Amato
    Department of Internal Medicine, The University of Texas Medical School Memorial Hermann Cancer Center, Houston, Texas 77030, USA
    Cancer Invest 30:415-21. 2012
    ..In carcinogenesis, methylation of DNA promoter regions results in inactivation of tumor-suppressing genes. MG98 was designed to inhibit DNA methyltransferases enzyme 1 production...
  35. doi Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer
    Robert J Amato
    Division of Oncology, Department of Internal Medicine, University of Texas Health Science Center at Houston Medical School, Memorial Hermann Cancer Center, Houston, TX 77030, USA
    Clin Genitourin Cancer 10:26-31. 2012
    ..We conducted a phase I study to evaluate the maximum tolerated dose (MTD) of combining these agents for potential additive or synergistic effects when treating progressive metastatic RCC (mRCC)...
  36. ncbi Thalidomide therapy for renal cell carcinoma
    Robert J Amato
    Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, 77030, Houston, TX, USA
    Crit Rev Oncol Hematol 46:S59-65. 2003
    ..To review the use of thalidomide as a therapeutic option for patients with metastatic renal cell carcinoma (RCC)...
  37. ncbi Metastatic renal cell carcinoma to the nose and ethmoid sinus
    Mohammadbagher Ziari
    Department of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, USA
    Urology 67:199. 2006
    ..The patient achieved a complete response both clinically and by magnetic resonance imaging, without any side effects. Late and rare sites of recurrences and treatment options are discussed...
  38. ncbi Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms
    Steven S Shen
    Department of Pathology, The Methodist Hospital, Baylor College of Medicine, Houston, TX 77030, USA
    Mod Pathol 18:933-40. 2005
    ..These results demonstrated high sensitivity and specificity of Ksp-cadherin for distal convoluted tubules, which can be used as adjunct for diagnosis of chromophobe RCC...
  39. ncbi Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine
    Lorenzo Cohen
    Department of Behavioral Science, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 243, Houston, TX 77030, USA
    Urol Oncol 7:119-24. 2002
    ..We prospectively examined quality of life (QOL) in patients with metastatic renal cell carcinoma treated with nephrectomy followed by heat shock protein peptide complex 96 (HSPPC-96) vaccine, a nontoxic, active, specific immunotherapy...
  40. doi Vaccine therapy for renal cancer
    Robert J Amato
    Genitourinary Oncology Program The Methodist Hospital Research Institute 6560 Fannin, Suite 2050, Houston, TX 77030, USA
    Expert Rev Vaccines 7:925-35. 2008
    ....
  41. ncbi Heat-shock protein-peptide complex-96 for the treatment of cancer
    Robert J Amato
    The Methodist Hospital Research Institute, Genitourinary Oncology Program, Houston, Texas, USA
    Expert Opin Biol Ther 7:1267-73. 2007
    ..This paper reviews the development and clinical trial progress of vitespen, an HSP peptide complex vaccine based on tumor-derived glycoprotein 96...
  42. ncbi 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy
    Robert J Amato
    The Methodist Hospital Research Institute, Genitourinary Oncology Program, 6560 Fannin, Suite 2050, Houston, Texas 77030, USA
    Expert Opin Biol Ther 7:1463-9. 2007
    ..With its minimal side effects and demonstrated ability to produce strong immune responses in patient populations, MVA-5T4 is a promising addition to the cancer therapy arsenal...
  43. doi Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors
    Ronald E Fisher
    Methodist Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
    J Nucl Med 49:899-906. 2008
    ....
  44. doi Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy
    Robert J Amato
    Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Clin Genitourin Cancer 5:422-6. 2007
    ..Because of the current preclinical and clinical evidence, further trials of MG98 as therapy for RCC would be of interest...
  45. ncbi Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus
    Robert J Amato
    Division of Oncology, Department of Internal Medicine, The University of Texas Health Science Center at Houston Medical School, Memorial Hermann Cancer Center, Houston, TX Electronic address
    Urol Oncol 32:345-54. 2014
    ..We have developed a model based on clinical parameters and patient stratification into risk groups to predict patients with RCC who will derive the most benefit from treatment with everolimus...
  46. pmc Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
    Putao Cen
    Division of Oncology, Department of Internal Medicine, University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
    Onco Targets Ther 5:217-24. 2012
    ..Future investigations will focus on everolimus combination therapy to treat PanNETs and the discovery of predictive biomarkers for response to everolimus...
  47. ncbi Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer
    Robert J Amato
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Invest New Drugs 20:413-7. 2002
    ..There were no objective responses. The most common toxicities were nausea, emesis, and thrombocytopenia. Irofulven, at the dose and schedule administered in this trial, showed no effect in metastatic renal cell cancer...
  48. ncbi The role of caveolin-1 in androgen insensitive prostate cancer
    Vladimir Mouraviev
    Scott Department of Urology, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas, USA
    J Urol 168:1589-96. 2002
    ..Caveolin-1 is a major structural component of caveolae, membrane micro-domains known to have important roles in signal transduction and lipid transport...